CD34+/CD38- Stem Cell Burden Could Predict Chronic Myeloid Leukemia Patients' Outcome

Area of Science:

• Hematology
• Oncology
• Stem Cell Biology

Background:

• Chronic Myeloid Leukemia (CML) patient outcomes are currently predicted by response to therapy.
• There is a need for biomarkers that predict CML outcomes before treatment initiation.
• This study investigates the impact of CD34+/CD38- stem cells (SCs) burden on CML treatment response and patient outcomes.

Purpose of the Study:

• To assess the prognostic value of CD34+/CD38- stem cells (SCs) burden in Chronic Myeloid Leukemia (CML) patients.
• To determine if pre-treatment SCs levels can predict treatment response and patient outcomes.
• To identify a novel biomarker for predicting CML progression and response to therapy.

Main Methods:

• Quantification of CD34+/CD38- stem cells (SCs) using flow cytometry in 65 chronic phase CML patients.
• SCs were measured before and after frontline imatinib (IM) therapy.
• Median follow-up duration of 18 months for all study participants.

Main Results:

• Pre-treatment CD34+/CD38- stem cells (SCs) frequency correlates with established prognostic markers.
• High pre-treatment SCs burden predicts poor molecular response and transformation to Acute Myeloid Leukemia (AML).
• Elevated SCs levels at diagnosis are associated with adverse patient outcomes and predict response to frontline therapy.

Conclusions:

• The percentage of CD34+/CD38- stem cells (SCs) at diagnosis serves as a biomarker for Chronic Myeloid Leukemia (CML) disease behavior.
• Pre-treatment SCs burden effectively predicts patient response to first-line Tyrosine Kinase Inhibitor (TKI) therapy.
• This finding supports the use of SCs quantification for personalized CML treatment strategies.